EUVIMEDEUVIMED entdecken
Editorial

Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?

David S McLaren, Nikolaos Kyriakakis, Khyatisha Seejore, Julie Lynch, Robert D Murray

Clinical Endocrinology · 2025

DOI: 10.1111/cen.15193 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von David S McLaren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds, UK. Hauptthemen laut MEDLINE: Acromegaly, Octreotide, Receptors, Somatostatin, Somatostatin. Die Arbeit nennt 15 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the current therapeutic modalities available to endocrinologists, control of GH and IGF‐I is now possible in almost all patients with acromegaly with multi‐modality therapy. Despite biochemical control of GH and IGF‐I, patients with acromegaly continue to experience impaired quality of life. Although there are likely multiple factors contributing to this dissatisfaction with current medical therapies, in particular the widely utilised injectable long‐acting somatostatin receptor ligands (iSRL), is a contributor. The iSRLs require intramuscular or deep subcutaneous injection with a wide bore needle that can be complicated by injection site pain, erythema, subcutaneous nodule formation, and for most individuals require attendance with a healthcare professional every 28 days to safely administered the medication. Two oral SRL (oSRL) formulations, Oral Octreotide Capsules and Paltusotine have been developed with clinical studies showing them to have promise as a therapeutic alternative to iSRL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyOctreotideReceptors, SomatostatinSomatostatinHumansAdministration, OralLigands

Stichwörter der Autor:innen

acromegalylanreotideligandoctreotideoralpaltusotinesomatostatin

Substanzen

LigandsOctreotideReceptors, SomatostatinSomatostatin

Autor:innen und Institutionen

  • Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds, UK.
  • Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK.

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

McLaren, D. S., Kyriakakis, N., Seejore, K., Lynch, J., & Murray, R. D. (2025). Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?. Clinical Endocrinology. https://doi.org/10.1111/cen.15193

Vancouver

McLaren DS, Kyriakakis N, Seejore K, Lynch J, Murray RD. Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?. Clinical Endocrinology. 2025. doi:10.1111/cen.15193

BibTeX
@article{McLaren2025,
  author = {McLaren, David S and Kyriakakis, Nikolaos and Seejore, Khyatisha and Lynch, Julie and Murray, Robert D},
  title = {Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?},
  journal = {Clinical Endocrinology},
  year = {2025},
  doi = {10.1111/cen.15193}
}
Kostenlos starten →